National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 37464 [2020-13321]
Download as PDF
<![CDATA[
37464
Federal Register / Vol. 85, No. 120 / Monday, June 22, 2020 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Fenoterol and
Certain Fenoterol Analogues for the
Treatment of Cancer
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; RFA AA–20–007
Medications Development for the Treatment
of Alcohol Use Disorder (AUD) or AlcoholRelated Organ Damage (AROD), or the
Combination of AUD and AROD (U01
Clinical Trial Optional).
Date: July 24, 2020.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Alcohol Abuse and
Alcoholism, 6700 B Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Ranga Srinivas, Ph.D.,
Chief Extramural Project Review Branch,
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health,
6700 B Rockledge Drive, Room 2114,
Bethesda, MD 20892, (301) 451–2067,
srinivar@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
B Subcommittee MID–B Review Committee
July 2020.
Date: July 13–15, 2020.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F30,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Ellen S. Buczko, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F30, Rockville, MD
20892–7616, 301–451–2676, ebuczko1@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–13321 Filed 6–19–20; 8:45 am]
BILLING CODE 4140–01–P
Dated: June 16, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–13327 Filed 6–19–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:08 Jun 19, 2020
Jkt 250001
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute on
Aging, an institute of the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an Exclusive
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the
Supplementary Information section of
this Notice to Paz Pharmaceuticals, LLC
of the State of Delaware.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before July 7, 2020 will be
considered.
SUMMARY:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Richard T. Girards, Jr., Esq.,
MBA, Senior Technology Transfer
Manager, National Institutes of Health,
NCI Technology Transfer Center by
email (richard.girards@nih.gov) or
phone (240–276–6825).
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
E–205–2006: Preparation of (R,R)fenoterol and (R,R)-or (R,S)-fenoterol
analogues and their use in treating
congestive heart failure
1. United States Provisional Patent
Application No. 60/837,161, filed 10 August
2006 (HHS Reference No. E–205–2006–0–
US–01);
2. United States Provisional Patent
Application No. 60/927,825, filed 03 May
2007 (HHS Reference No. E–205–2006–1–
US–01);
3. United States Patent Application No. 12/
376,945, filed 09 February 2009 (HHS
Reference No. E–205–2006–2–US–13);
4. United States Patent No. 8,703,826,
issued 22 April 2014 (HHS Reference No. E–
205–2006–2–US–15);
5. United States Patent No. 9,522,871,
issued 20 December 2016 (HHS Reference
No. E–205–2006–2–US–19);
6. United States Patent No. 9,908,841,
issued 06 March 2018 (HHS Reference No. E–
205–2006–2–US–22);
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 85, Number 120 (Monday, June 22, 2020)]
[Notices]
[Page 37464]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-13321]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Microbiology, Infectious Diseases and AIDS
Initial Review Group; Microbiology and Infectious Diseases B
Subcommittee MID-B Review Committee July 2020.
Date: July 13-15, 2020.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F30,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Ellen S. Buczko, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F30,
Rockville, MD 20892-7616, 301-451-2676, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: June 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-13321 Filed 6-19-20; 8:45 am]
BILLING CODE 4140-01-P
